Innate Pharma S.A. (IPHA)
| Market Cap | 201.78M -3.9% |
| Revenue (ttm) | 10.57M -55.2% |
| Net Income | -57.74M |
| EPS | -0.65 |
| Shares Out | 93.79M |
| PE Ratio | n/a |
| Forward PE | 12.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,882 |
| Open | 2.220 |
| Previous Close | 2.160 |
| Day's Range | 2.220 - 2.260 |
| 52-Week Range | 1.170 - 2.710 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+209.74%) |
| Earnings Date | Sep 17, 2026 |
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant... [Read more]
Financial Performance
In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IPHA stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 209.74% from the latest price.
News
Innate Pharma price target raised to $9 from $8 at BTIG
BTIG analyst Jeet Mukherjee raised the firm’s price target on Innate Pharma (IPHA) to $9 from $8 and keeps a Buy rating on the shares. The firm notes that the…
Innate Pharma SA To Hold Conference Call Transcript
Innate Pharma SA To Hold Conference Call Transcript
Innate Pharma Secures €30M, Extends Cash Runway Into 2028
Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs an...
Innate Pharma Transcript: Investor update
A €30 million equity raise and a strategic partnership with Sobi extend the cash runway through Q1 2028, enabling continued advancement of key programs including lacutamab, IPH4502, and the ADC portfolio. Key clinical data for IPH4502 and monalizumab are expected later this year.
Innate Pharma Press release: Investor update
Innate Pharma issued a press release on August 14, 2026, disclosing material business information to investors.
Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p...
Innate Pharma Announces Conference Call and Webcast
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares
Regulatory News: NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced t...
Innate Pharma Slides: Company presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Innate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary Shares
Regulatory News: NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announc...
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
As previously reported, Leerink upgraded Innate Pharma (IPHA) to Outperform from Market Perform with a price target of $4, up from $3, citing enthusiasm for the company’s wholly-owned IPH4502. The…
Innate Pharma upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Innate Pharma (IPHA) to Outperform from Market Perform with a price target of $4, up from $3.
Innate Pharma price target raised to $7 from $5 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Innate Pharma (IPHA) to $7 from $5 and keeps a Buy rating on the shares. Innate Pharma’s lacutamab partnership…
Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO
(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initi...
Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study
Sobi and Innate Pharma (IPHA) announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key…
Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed
Innate also announced the appointment of Markus Jensen as chief medical officer and member of the executive leadership team, effective September 1, succeeding Sonia Quaratino. Jensen joined Innate Pha...
Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma
(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutane...
Swedish Orphan Biovitrum AB: Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they h...
Innate Pharma SA: Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome Markus Jensen appointed Chief M...
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have...
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its ...
Innate Pharma SA: Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that they have entered a strategic p...
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today...
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that they have entered a strategic partn...
Innate Pharma SA: Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today anno...